A critical evaluation of the ubiquitin–proteasome system in Parkinson's disease
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The evidence for impairment in the ubiquitin proteasome system (UPS) in Parkinson's disease (PD) is mounting and becoming increasingly more convincing. However, it is presently unclear whether UPS dysfunction is a cause or result of PD pathology, a crucial distinction which impedes both the understanding of disease pathogenesis and the development of effectual therapeutic approaches. Recent findings discussed within this review offer new insight and provide direction for future research to conclusively resolve this debate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · cited 1×
“The identification of α-synuclein as the major, filamentous protein component of LBs [3], in addition to the linkage of missense mutations (A53T, A30P, E46K) and genomic duplication and triplication of the α-synuclein gene with autosomal dominant PD [4-8], is indicative of a key role for α-synuclein in disease pathoge…”
BackgroundCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 5×
“Under normal conditions, Nrf2 is sequestered in the cytosol by the actin-binding protein Keap1 [206].”
BackgroundInfluentialHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869 · cited 1×
“This suggests that loss of vesicular or membrane-binding ability due to mutation [123] or oxidative damage [81,124] would enhance 20S-mediated cleavage of αsynuclein, increasing the generation of truncated fragments.”
BackgroundDrosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 22×
“Intriguingly, knockout of the PINK1 gene in Drosophila led to defects in mitochondrial morphology and degeneration of dopaminergic neurons, a phenotype which was rescued by parkin overexpression [228,229].”
BackgroundInfluentialMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 22×
“Intriguingly, knockout of the PINK1 gene in Drosophila led to defects in mitochondrial morphology and degeneration of dopaminergic neurons, a phenotype which was rescued by parkin overexpression [228,229].”
BackgroundInfluentialExtrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686 · cited 1×
“A reduction in neuronal activity would not only decrease BDNF expression and synaptic release [70-73], but based on the findings of Fortin and associates, would also be expected to increase the amount of membrane-bound α-synuclein localized to the synapse [67,68].”
BackgroundParkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 14×
“Interestingly, overexpression of LRRK2 led to the formation of inclusions in a small fraction of cells, which was exacerbated by the coexpression of parkin [217].”
InfluentialChaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease
Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M.-Y., & Bonini, N. M. (2002) · Science · doi:10.1126/science.1067389 · Cited by 1,227
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203 · cited 1×
“As deletion of the parkin gene produced a similar phenotype [230,231] that could not likewise be reversed by overexpression of PINK1 [228, 229], and deletion of both the parkin and PINK1 genes does not lead to an exacerbated phenotype, it is believed that PINK1 is upstream of parkin in a signaling cascade that regulat…”
BackgroundKinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001) · Science · doi:10.1126/science.1060627 · Cited by 1,053
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879 · cited 1×
“Modulation of aggregation potential of α-synuclein—The precipitating basis of α-synuclein aggregation in synucleinopathies is controversial, though broadly speculated to arise from an increase in α-synuclein protein expression (either through gene triplication or altered transcriptional or translational activities), e…”
BackgroundCabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818 · cited 15×
“Given that Nrf2 is a component of the transcription complex that binds to the cis-acting element ARE (antioxidant response element), which regulates the expression of proteins that are protective against oxidative stress (e.g. glutathione S-transferases, glutamyl cysteine ligase, and NADPH quinone oxidoreductase) [202…”
BackgroundInfluentialA common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
Isackson, P. J., Huntsman, M. M., Murray, K. D., & Gall, C. M. (1991) · Neuron · doi:10.1016/0896-6273(91)90234-q · Cited by 711 · cited 1×
“A reduction in neuronal activity would not only decrease BDNF expression and synaptic release [70-73], but based on the findings of Fortin and associates, would also be expected to increase the amount of membrane-bound α-synuclein localized to the synapse [67,68].”
BackgroundProteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653 · cited 1×
“caspase-like activity was detected in the SN of PD patients when compared to age-matched controls [31-34].”
ResultAltered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573 · cited 2×
“In line with these findings, immunoblotting and histological techniques revealed a decrease in subunits of the 20S proteasome and the PA700/19S complex in the SN of PD patients, while protein levels where unchanged or increased in extranigral brain regions [31,32,35].”
ResultGlobal changes to the ubiquitin system in Huntington's disease
Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K.-Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H., & Kopito, R. R. (2007) · Nature · doi:10.1038/nature06022 · Cited by 497 · cited 1×
“UPS impairment has also been observed in cell culture and animal models overexpressing mutant huntingtin protein [129,140-144], and consistent with data proposing a protective effect of aggregation due to sequestration of toxic species, treatment with a compound that increases inclusion formation prevents huntingtin-m…”
BackgroundStewart, D., Killeen, E., Naquin, R., Alam, S., & Alam, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209195200 · Cited by 463 · cited 15×
“Given that Nrf2 is a component of the transcription complex that binds to the cis-acting element ARE (antioxidant response element), which regulates the expression of proteins that are protective against oxidative stress (e.g. glutathione S-transferases, glutamyl cysteine ligase, and NADPH quinone oxidoreductase) [202…”
BackgroundInfluentialDegradation of α-Synuclein by Proteasome
Bennett, M. C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N., & Mouradian, M. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.33855 · Cited by 417
Aβ inhibits the proteasome and enhances amyloid and tau accumulation
Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M., & LaFerla, F. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.014 · Cited by 384
Tofaris, G. K., Layfield, R., & Spillantini, M. G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03115-5 · Cited by 363 · cited 2×
“Given the natively unfolded structure of αsynuclein, it has now been shown that wild-type α-synuclein can be degraded by a ubiquitinindependent proteasome pathway [21,120,121].”
BackgroundPINK1 protein in normal human brain and Parkinson's disease
Gandhi, S. (2006) · Brain · doi:10.1093/brain/awl114 · Cited by 342 · cited 2×
“PINK1, a highly conserved kinase that is localized to the inner and outer mitochondrial membranes [221-224], has been identified as the gene locus for PARK6-linked PD, which is characterized by an earlier age of onset than sporadic PD [224].”
BackgroundBedford, L., Hay, D., Devoy, A., Paine, S., Powe, D. G., Seth, R., Gray, T., Topham, I., Fone, K., Rezvani, N., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2218-08.2008 · Cited by 327 · cited 3×
“As restriction of Rpt2/PSMC1 knockdown to THpositive neurons is particularly relevant to PD pathology, it is disappointing that autonomic dysfunction leading to premature death by 1 month of age prevents a full behavioral assessment of these mice [52].”
BackgroundPINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons
Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. S. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002455 · Cited by 316 · cited 2×
“The deletion of PINK1 also leads to an increased activation of the mitochondrial cell-death pathway, as well as an elevation of ROS levels [232].”
BackgroundDirect evidence for S-nitrosation of mitochondrial complex I
Burwell, L. S., Nadtochiy, S. M., Tompkins, A. J., Young, S., & Brookes, P. S. (2006) · Biochemical Journal · doi:10.1042/bj20051435 · Cited by 274 · cited 1×
“Loss of DJ-1 function is further implicated in PD pathogenesis by the observation that glutathione levels are decreased in the SN in early stages of PD [196], as well as the demonstration that depletion of glutathione leads to an age-related neurodegeneration of the nigrostriatal pathway by oxidation-dependent inhibit…”
BackgroundNorris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273 · cited 3×
“As the amino acid residues 125-129 in the C-terminus of α-synuclein have been shown to be required for catecholmediated inhibition of synuclein aggregation [89,115], it is interesting that a mouse model overexpressing truncated wild-type α-synuclein (1-120), which lacks the catechol-interaction site, develops insolubl…”
BackgroundParkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis
Jiang, H., Ren, Y., Zhao, J., & Feng, J. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh180 · Cited by 239 · cited 1×
“In particular taking into consideration that parkin has been shown to exert a significant neuroprotective effect against various toxic insults, including manganese-induced cell death, α-synuclein toxicity, proteasomal dysfunction, Pael-R and P38/JTv-1 accumulation, kainateinduced excitotoxicity, mitochondrial-dependen…”
BackgroundAre ubiquitination pathways central to Parkinson’s disease?
Giasson, B. I., & Lee, V. M.-Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00509-9 · Cited by 234 · cited 1×
“Given the detrimental consequences of unregulated protein degradation, the UPS utilizes a class of enzymes to covalently link ubiquitin polypeptide chains to proteins, marking those proteins as substrates for the proteasome and allowing for targeted and selective degradation (reviewed in [14,15]).”
BackgroundA molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides
Gallardo, G., Schlüter, O. M., & Südhof, T. C. (2008) · Nature Neuroscience · doi:10.1038/nn2058 · Cited by 145
Chinta, S. J., Kumar, M. J., Hsu, M., Rajagopalan, S., Kaur, D., Rane, A., Nicholls, D. G., Choi, J., & Andersen, J. K. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3885-07.2007 · Cited by 145 · cited 1×
“Loss of DJ-1 function is further implicated in PD pathogenesis by the observation that glutathione levels are decreased in the SN in early stages of PD [196], as well as the demonstration that depletion of glutathione leads to an age-related neurodegeneration of the nigrostriatal pathway by oxidation-dependent inhibit…”
BackgroundKordower, J. H., Kanaan, N. M., Chu, Y., Suresh Babu, R., Stansell, J., Terpstra, B. T., Sortwell, C. E., Steece-Collier, K., & Collier, T. J. (2006) · Annals of Neurology · doi:10.1002/ana.20935 · Cited by 141
Marx, F. P., Soehn, A. S., Berg, D., Melle, C., Schiesling, C., Lang, M., Kautzmann, S., Strauss, K. M., Franck, T., Engelender, S., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-6734com · Cited by 52 · cited 18×
“In addition, the accumulation of ubiquitinated proteins, heat shock proteins/chaperones, and components of the UPS within LBs provides further support for a central role of UPS dysfunction in the etiopathogenesis of PD [36-41].”
BackgroundInfluential
Cited by
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, B. T., McLean, P. J., & Unni, V. K. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1560-11.2011 · Cited by 377
Ganguly, G., Chakrabarti, S., Chatterjee, U., & Saso, L. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s130514 · Cited by 294
α‐Synuclein oligomers and clinical implications for Parkinson disease
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013) · Annals of Neurology · doi:10.1002/ana.23746 · Cited by 292
Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1
Nucifora, F. C., Nucifora, L. G., Ng, C.-H., Arbez, N., Guo, Y., Roby, E., Shani, V., Engelender, S., Wei, D., Wang, X.-F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11792 · Cited by 82
Metadata
- Authors
- Cook, C., & Petrucelli, L.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 1792
- Issue
- 7
- Pages
- 664-675
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2116847871
- Cited by
- 113
- References
- 42
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.